Intrarosa (Prasterone)

Prasterone (DHEA) in Intrarosa is converted locally within the vaginal mucosa into active androgens and estrogens. These hormones bind to their respective receptors, stimulating cellular growth, increasing glycogen production, and enhancing natural lubrication, which together reverse atrophic changes.

The dosage of Intrarosa is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. The product is supplied as a vaginal insert, and the prescriber specifies the frequency and duration of use.

Intrarosa is intended for postmenopausal women and is not recommended for use during pregnancy or lactation. Safety data for these populations are lacking, and the product should be avoided unless a specialist determines a clear benefit outweighs potential risks.

To place an order, submit an enquiry on the Intrarosa product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Intrarosa delivers a locally acting androgen (DHEA) that is converted to both androgens and estrogens within the vagina, offering a dual‑hormone effect. Conventional treatments often use systemic estrogen alone, which may have broader systemic exposure. Intrarosa’s local conversion can provide targeted symptom relief with potentially fewer systemic effects.

Intrarosa should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Intrarosa is supplied as a vaginal insert. The patient inserts the device into the vagina according to the prescriber’s instructions, typically at bedtime, allowing the insert to dissolve and release prasterone locally over a defined period.

Serious risks include severe allergic reactions such as anaphylaxis, significant vulvar edema, persistent vaginal bleeding, and systemic hormonal effects like hirsutism or mood changes. Patients should seek immediate medical attention if they experience any of these symptoms.

Intrarosa should not be used by individuals with known hypersensitivity to prasterone or any excipients, those with active genital infections, or women who are pregnant or breastfeeding. It is also contraindicated in patients receiving systemic hormone therapy unless specifically advised by a qualified healthcare professional.